Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.33 |
| ▸ | TACR1 | P25103 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | FABP4 | P15090 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL5208788 | 0.99 | TSHR (0.42) | TSHRDAOHCAR2SCN10ATACR1 | |
| SCHEMBL20470736 | 0.83 | TSHR (0.43) | TSHRDAOHCAR2SCN10ATACR1 | |
| SCHEMBL4883243 | 0.75 | TSHR (0.44) | TSHRHCAR2CA1CA2CA7 | |
| SCHEMBL4899447 | 0.73 | TSHR (0.42) | TSHRHCAR2SLC6A4 | |
| SCHEMBL4883231 | 0.71 | TSHR (0.46) | TSHRTACR1CA1CA2CA7 | |
| SCHEMBL4886521 | 0.69 | ALDH1A1 (0.39) | TSHRHCAR2SCN10A | |
| SCHEMBL31233365 | 0.67 | HCAR2 (0.35) | TSHRDAOHCAR2 | |
| SCHEMBL31233419 | 0.67 | TSHR (0.35) | TSHRHCAR2SCN10A | |
| SCHEMBL5311581 | 0.66 | TSHR (1.00) | TSHRTACR1CA1CA2CA7 | |
| SCHEMBL27380 | 0.66 | TSHR (1.00) | TSHRTACR1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083583-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF | SAGIMET BIOSCIENCES INC (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3083583-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF | SAGIMET BIOSCIENCES INC (US) | 2020-11-18 | — | — | EP | disclosed |
| CN-106061963-B | Heterocyclic modulators of lipid synthesis and combinations thereof | 3-V生物科学股份有限公司 | 2019-10-22 | — | — | CN | disclosed |
| EP-2870150-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3 V BIOSCIENCES INC (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-2870150-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3 V BIOSCIENCES INC (US) | 2019-06-19 | — | — | EP | disclosed |
| US-10226449-B2 | Heterocyclic modulators of lipid synthesis and combinations thereof | 3-V BIOSCIENCES, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10226449-B2 | Heterocyclic modulators of lipid synthesis and combinations thereof | 3-V BIOSCIENCES, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10118913-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2018-11-06 | — | — | US | disclosed |
| US-10053450-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180222892-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| WO-2015095767-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF | 3-V BIOSCIENCES, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| EP-2870150-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V Biosciences, Inc. (US) | 2015-05-13 | — | — | EP | disclosed |
| WO-2014008197-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| WO-2014008197-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | PFIZER INC | 2008-07-24 | — | — | US | disclosed |
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | PFIZER INC | 2008-07-24 | — | — | US | disclosed |
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | PFIZER INC | 2008-07-24 | — | — | US | disclosed |
| US-20080132549-A1 | Sulphur-Linked Imidazone Compounds for the Treatment of Hiv/Aids | PFIZER INC. (US) | 2008-06-05 | — | — | US | disclosed |
| EP-1838679-A1 | IMIDAZOLE DERIVATIVES AS ENZYME REVERSE TRANSCRIPTASE MODULATORS | Pfizer Limited (GB) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006072833-A1 | IMIDAZOLE DERIVATIVES AS ENZYME REVERSE TRANSCRIPTASE MODULATORS | PFIZER LIMITED (GB) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10118913-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, FADS2 | TSHR 3069/4885DAO 1681/4885HCAR2 512/4885 |
| US-10053450-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, FADS2 | TSHR 3069/4885DAO 1681/4885HCAR2 512/4885 |
| US-20180222892-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | TSHR 3069/4885DAO 1681/4885HCAR2 512/4885 |
| US-20080132549-A1 | Sulphur-Linked Imidazone Compounds for the Treatment of Hiv/Aids | SPR, TPMT, IMPDH1 | TSHR 3874/4885DAO 1574/4885HCAR2 3972/4885 |
| US-10226449-B2 | Heterocyclic modulators of lipid synthesis and combinations thereof | FASN, FADS1, COASY | TSHR 3343/4885DAO 2299/4885HCAR2 363/4885 |
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | POLRMT, POLR1G, POLR2A | TSHR 1981/4885DAO 2113/4885HCAR2 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.